Privia Health Group (NASDAQ:PRVA) Director Matthew Shawn Morris Sells 16,550 Shares

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 16,550 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $25.00, for a total transaction of $413,750.00. Following the completion of the transaction, the director owned 68,188 shares in the company, valued at approximately $1,704,700. This represents a 19.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Matthew Shawn Morris also recently made the following trade(s):

• On Thursday, February 26th, Matthew Shawn Morris sold 7,788 shares of Privia Health Group stock. The stock was sold at an average price of $24.99, for a total value of $194,622.12.
• On Friday, December 12th, Matthew Shawn Morris sold 13,647 shares of Privia Health Group stock. The stock was sold at an average price of $25.01, for a total transaction of $341,311.47.

Privia Health Group Stock Up 1.2%

NASDAQ:PRVA traded up $0.29 during mid-day trading on Monday, hitting $24.04. 1,472,614 shares of the company traded hands, compared to its average volume of 813,700. The stock’s fifty day moving average price is $23.07 and its 200-day moving average price is $23.50. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of 141.41, a price-to-earnings-growth ratio of 1.59 and a beta of 0.82. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $26.51.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.21. The business had revenue of $541.17 million during the quarter, compared to analyst estimates of $516.61 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The company’s revenue was up 17.4% on a year-over-year basis. During the same period last year, the firm posted $0.21 EPS. Equities analysts predict that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Hedge Funds Weigh In On Privia Health Group

Institutional investors have recently modified their holdings of the stock. Van Berkom & Associates Inc. lifted its holdings in shares of Privia Health Group by 30.1% in the 3rd quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock worth $93,987,000 after buying an additional 873,344 shares during the period. Vanguard Group Inc. lifted its stake in Privia Health Group by 5.3% in the third quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after acquiring an additional 607,447 shares during the period. ArrowMark Colorado Holdings LLC grew its holdings in Privia Health Group by 139.4% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock worth $19,946,000 after acquiring an additional 489,866 shares in the last quarter. Algert Global LLC increased its position in Privia Health Group by 277.4% during the 3rd quarter. Algert Global LLC now owns 484,304 shares of the company’s stock valued at $12,059,000 after purchasing an additional 355,966 shares during the period. Finally, Freestone Grove Partners LP raised its holdings in shares of Privia Health Group by 40.6% in the 4th quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock valued at $28,768,000 after purchasing an additional 350,194 shares in the last quarter. 94.48% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on PRVA shares. Evercore boosted their target price on Privia Health Group from $28.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Piper Sandler reiterated an “overweight” rating and set a $36.00 price objective on shares of Privia Health Group in a research report on Thursday. Royal Bank Of Canada assumed coverage on shares of Privia Health Group in a report on Friday, January 9th. They issued an “outperform” rating and a $31.00 target price for the company. Canaccord Genuity Group lifted their price target on shares of Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. Finally, JPMorgan Chase & Co. increased their price objective on shares of Privia Health Group from $32.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.93.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.